WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H206443
CAS#: 870964-67-3
Description: Evocalcet is a calcium-sensing receptor agonist. The calcium-sensing receptor (CaSR) is a Class C G-protein coupled receptor which senses extracellular levels of calcium ion. The calcium-sensing receptor controls calcium homeostasis by regulating the release of parathyroid hormone (PTH). CaSR is expressed in all of the organs of the digestive system. CaSR plays a key role in gastrointestinal physiological function and in the occurrence of digestive disease. High dietary Ca2+ may stimulate CaSR activation and could both inhibit tumor development and increase the chemotherapeutic sensitivity of cancer cells in colon cancer tissues.
Hodoodo Cat#: H206443
Name: Evocalcet
CAS#: 870964-67-3
Chemical Formula: C24H26N2O2
Exact Mass: 374.20
Molecular Weight: 374.480
Elemental Analysis: C, 76.98; H, 7.00; N, 7.48; O, 8.54
Synonym: MT-4580; MT 4580; MT4580; KHK-7580; KHK7580; KHK 7580; Evocalcet;
IUPAC/Chemical Name: 2-(4-((S)-3-(((R)-1-(naphthalen-1-yl)ethyl)amino)pyrrolidin-1-yl)phenyl)acetic acid
InChi Key: RZNUIYPHQFXBAN-XLIONFOSSA-N
InChi Code: InChI=1S/C24H26N2O2/c1-17(22-8-4-6-19-5-2-3-7-23(19)22)25-20-13-14-26(16-20)21-11-9-18(10-12-21)15-24(27)28/h2-12,17,20,25H,13-16H2,1H3,(H,27,28)/t17-,20+/m1/s1
SMILES Code: O=C(O)CC1=CC=C(N2C[C@@H](N[C@@H](C3=C4C=CC=CC4=CC=C3)C)CC2)C=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | Evocalcet has an activating effect on calcium sensing receptor (CaSR) extracted from patent WO 2017061621 A1, compound A. |
| In vitro activity: | To confirm the agonistic action of evocalcet on human CaR (hCaR), the cytoplasmic Ca2+ concentrations ([Ca2+]i) were examined in HEK293 cells stably expressing hCaR (hCaR-HEK293). Evocalcet evoked concentration-dependent increases in [Ca2+]i (Fig 2A). The EC50 of evocalcet for [Ca2+]i was 92.7 nM. This study also investigated the effects of evocalcet on the [Ca2+]i that were elicited by increasing the extracellular calcium concentration. When the concentration of evocalcet was increased, the concentration-response curves shifted to a lower range of extracellular calcium concentration (Fig 2B). Reference: PLoS One. 2018; 13(4): e0195316. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882164/ |
| In vivo activity: | To evaluate the emetic effects, 2 miniature pigs were intravenously treated with cisplatin (2 and 5 mg/kg), and 4 were orally treated with cinacalcet (10, 30 and 100 mg/kg) or evocalcet (0.3, 1, 3, and 10 mg/kg). Cisplatin induced vomiting at both doses in 2/2 pigs. Cinacalcet also induced vomiting in 1/4 pigs at 10 mg/kg, 2/4 pigs at 30 mg/kg, and 3/4 pigs at 100 mg/kg. In contrast, no emetic-like symptoms were observed at any dose of evocalcet (Table 3). Reference: PLoS One. 2021; 16(1): e0245785. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822337/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMF | 5.0 | 13.35 | |
| DMSO | 5.0 | 13.35 | |
| DMSO:PBS (pH 7.2) (1:2) | 0.3 | 0.81 |
The following data is based on the product molecular weight 374.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, Hisada Y, Yanagida T, Miyazaki H, Wada M, Akizawa T, Fukagawa M. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. PLoS One. 2018 Apr 3;13(4):e0195316. doi: 10.1371/journal.pone.0195316. PMID: 29614098; PMCID: PMC5882164. 2. Tokunaga S, Kawata T. The effect of evocalcet on vagus nerve activity of the gastrointestinal tract in miniature pigs. PLoS One. 2021 Jan 22;16(1):e0245785. doi: 10.1371/journal.pone.0245785. PMID: 33481922; PMCID: PMC7822337. 3. Sakai M, Tokunaga S, Kawai M, Murai M, Kobayashi M, Kitayama T, Saeki S, Kawata T. Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism. PLoS One. 2020 Apr 28;15(4):e0232428. doi: 10.1371/journal.pone.0232428. PMID: 32343734; PMCID: PMC7188245. |
| In vitro protocol: | 1. Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, Hisada Y, Yanagida T, Miyazaki H, Wada M, Akizawa T, Fukagawa M. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. PLoS One. 2018 Apr 3;13(4):e0195316. doi: 10.1371/journal.pone.0195316. PMID: 29614098; PMCID: PMC5882164. |
| In vivo protocol: | 1. Tokunaga S, Kawata T. The effect of evocalcet on vagus nerve activity of the gastrointestinal tract in miniature pigs. PLoS One. 2021 Jan 22;16(1):e0245785. doi: 10.1371/journal.pone.0245785. PMID: 33481922; PMCID: PMC7822337. 2. Sakai M, Tokunaga S, Kawai M, Murai M, Kobayashi M, Kitayama T, Saeki S, Kawata T. Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism. PLoS One. 2020 Apr 28;15(4):e0232428. doi: 10.1371/journal.pone.0232428. PMID: 32343734; PMCID: PMC7188245. |
1: Akizawa T, Ikejiri K, Kondo Y, Endo Y, Fukagawa M. Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism. Ther Apher Dial. 2019 Sep 5;24(3):248–57. doi: 10.1111/1744-9987.13434. Epub ahead of print. PMID: 31486206; PMCID: PMC7317959.
2: Sakai M, Tokunaga S, Kawai M, Murai M, Kobayashi M, Kitayama T, Saeki S, Kawata T. Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism. PLoS One. 2020 Apr 28;15(4):e0232428. doi: 10.1371/journal.pone.0232428. PMID: 32343734; PMCID: PMC7188245.
3: Parfrey PS. Evocalcet in the management of secondary hyperparathyroidism in dialysis patients. Kidney Int. 2018 Oct;94(4):661-662. doi: 10.1016/j.kint.2018.06.022. PMID: 30243312.
4: Fukagawa M, Shimazaki R, Akizawa T; Evocalcet study group. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2018 Oct;94(4):818-825. doi: 10.1016/j.kint.2018.05.013. Epub 2018 Jul 24. PMID: 30049473.
5: Shigematsu T, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group. Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients. Clin Exp Nephrol. 2019 Feb;23(2):258-267. doi: 10.1007/s10157-018-1635-6. Epub 2018 Aug 29. PMID: 30159688; PMCID: PMC6510802.
6: Tokunaga S, Endo Y, Kawata T. [Pharmacological and clinical profiles of a novel calcimimetic, evocalcet (ORKEDIA®)]. Nihon Yakurigaku Zasshi. 2019;154(1):35-43. Japanese. doi: 10.1254/fpj.154.35. PMID: 31308348.
7: Hamano N, Endo Y, Kawata T, Fukagawa M. Development of evocalcet for unmet needs among calcimimetic agents. Expert Rev Endocrinol Metab. 2020 Sep;15(5):299-310. doi: 10.1080/17446651.2020.1780911. Epub 2020 Jun 18. PMID: 32552012.
8: Tsuruya K, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group. Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients. Clin Exp Nephrol. 2019 Jun;23(6):739-748. doi: 10.1007/s10157-019-01692-y. Epub 2019 Apr 6. Erratum in: Clin Exp Nephrol. 2019 Jul 5;: PMID: 30955188; PMCID: PMC6586709.
9: Shigematsu T, Shimazaki R, Fukagawa M, Akizawa T. Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan. Clin Pharmacol. 2018 Sep 11;10:101-111. doi: 10.2147/CPAA.S171044. PMID: 30254496; PMCID: PMC6141109.
10: Yokoyama K, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group. Long- Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis. Sci Rep. 2019 Apr 23;9(1):6410. doi: 10.1038/s41598-019-42017-z. PMID: 31015494; PMCID: PMC6478860.
11: Takeuchi Y, Nishida Y, Kondo Y, Imanishi Y, Fukumoto S. Evocalcet in patients with primary hyperparathyroidism: an open-label, single-arm, multicenter, 52-week, dose-titration phase III study. J Bone Miner Metab. 2020 Sep;38(5):687-694. doi: 10.1007/s00774-020-01097-y. Epub 2020 Apr 9. PMID: 32274572.
12: Akizawa T, Shimazaki R, Fukagawa M; Evocalcet Study Group. Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study. PLoS One. 2018 Oct 31;13(10):e0204896. doi: 10.1371/journal.pone.0204896. PMID: 30379826; PMCID: PMC6209414.
13: Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, Hisada Y, Yanagida T, Miyazaki H, Wada M, Akizawa T, Fukagawa M. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. PLoS One. 2018 Apr 3;13(4):e0195316. doi: 10.1371/journal.pone.0195316. PMID: 29614098; PMCID: PMC5882164.
14: Miyazaki H, Ikeda Y, Sakurai O, Miyake T, Tsubota R, Okabe J, Kuroda M, Hisada Y, Yanagida T, Yoneda H, Tsukumo Y, Tokunaga S, Kawata T, Ohashi R, Fukuda H, Kojima K, Kannami A, Kifuji T, Sato N, Idei A, Iguchi T, Sakairi T, Moritani Y. Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism. Bioorg Med Chem Lett. 2018 Jun 15;28(11):2055-2060. doi: 10.1016/j.bmcl.2018.04.055. Epub 2018 Apr 24. PMID: 29724589.
15: Tsuruya K, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group. Correction to: Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients. Clin Exp Nephrol. 2019 Sep;23(9):1173. doi: 10.1007/s10157-019-01758-x. Erratum for: Clin Exp Nephrol. 2019 Jun;23(6):739-748. PMID: 31278658; PMCID: PMC6828059.
16: Xie J, Li X, Chen Y, Chen M, Mao N, Fan J. Efficacy and safety of evocalcet in treatment of secondary hyperparathyroidism in chronic kidney disease on hemodialysis patients: A protocol for a systematic review and meta-analysis. Medicine (Baltimore). 2020 Nov 13;99(46):e22566. doi: 10.1097/MD.0000000000022566. PMID: 33181644; PMCID: PMC7668479.
17: Narushima K, Maeda H, Shiramoto M, Endo Y, Ohtsuka S, Nakamura H, Nagata Y, Uchimura T, Kannami A, Shimazaki R, Fukagawa M, Akizawa T. Assessment of CYP- Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans. Clin Transl Sci. 2019 Jan;12(1):20-27. doi: 10.1111/cts.12588. Epub 2018 Oct 24. PMID: 30238620; PMCID: PMC6342237.
18: Akizawa T, Shimazaki R, Shiramoto M, Fukagawa M; Evocalcet Study Group. Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study. Clin Drug Investig. 2018 Oct;38(10):945-954. doi: 10.1007/s40261-018-0687-4. PMID: 30168004; PMCID: PMC6182462.
19: Shigematsu T, Asada S, Endo Y, Kawata T, Fukagawa M, Akizawa T. Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis. Int J Nephrol Renovasc Dis. 2020 May 12;13:97-106. doi: 10.2147/IJNRD.S243210. PMID: 32494184; PMCID: PMC7229806.
20: Srinivas NR. Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in- Human Phase I Study. Clin Drug Investig. 2019 Jan;39(1):105-107. doi: 10.1007/s40261-018-0738-x. PMID: 30632108.
